other material
confidence high
sentiment positive
materiality 0.70
Arcus reports ARC-20 casdatifan data: 1L PFS 69% at 12 months, 2L median PFS 14.5 months
Arcus Biosciences, Inc.
- First-line casdatifan + zimberelimab (n=30): 50% confirmed ORR, 86%/69% landmark PFS at 6/12 months, 6.7% primary progression; median follow-up 11.5 months.
- Second-line casdatifan + cabozantinib (n=43): median PFS 14.5 months, 18-month OS 77%, cORR 44%, primary progression 5%; median follow-up 21.3 months.
- Late-line casdatifan monotherapy (n=121): median OS 35 months, median PFS 13 months, cORR 36% across four pooled cohorts with 28 months median follow-up.
- Casdatifan + ipilimumab + zimberelimab: 1 of 24 scanned patients (4%) had primary progression at 3 months; 31 dosed, no unexpected safety signals.
- Data cutoff Sept 4, 2026; presented Oct 20, 2026. No unexpected safety signals in any cohort; Grade 3+ immune-mediated AEs consistent with ipilimumab/nivolumab.